Compare Hasbro, Inc. (HAS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Summit Therapeutics Inc — how do they compare? Hasbro, Inc. trades at $87.49 (market cap $11.53B), while Summit Therapeutics Inc trades at $14.41 (market cap $10.48B). The key difference: Hasbro, Inc. and Summit Therapeutics Inc are close in size by market cap, and Hasbro, Inc. pays a 3.44% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HAS | SMMT | |
|---|---|---|
Market Cap | $11.53B | $10.48B |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $29.32 |
52-Week Low | $70.95 | $13.05 |
Enterprise Value | $13.80B | $9.90B |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $81.56, showing minimal daily movement with a 0.01% gain. The stock exhibits a bearish technical signal, with RSI indicating overbought conditions near-term. Fundamentally, the company reported a net loss of -$322.4M in 2025 despite revenue growth to $4.7B, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights upcoming Q2 2026 earnings and new product launches like Blooms by Play-Doh targeting adult consumers.
The outlook remains mixed with analyst consensus leaning bullish (51.5% buy ratings) and a $104.75 price target suggesting 28% upside. Key risks include persistent negative profit margins, high debt levels, and competitive pressures in the toy industry. Earnings performance on July 21 will be critical for near-term direction.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
